MRI Enhancement in Stromal Tissue Surrounding Breast Tumors: Association with Recurrence Free Survival following Neoadjuvant Chemotherapy

Rationale and Objectives Normal-appearing stromal tissues surrounding breast tumors can harbor abnormalities that lead to increased risk of local recurrence. The objective of this study was to develop a new imaging methodology to characterize the signal patterns of stromal tissue and to investigate their association with recurrence-free survival following neoadjuvant chemotherapy. Materials and Methods Fifty patients with locally-advanced breast cancer were imaged with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before (V1) and after one cycle (V2) of adriamycin-cytoxan therapy. Contrast enhancement in normal-appearing stroma around the tumor was characterized by the mean percent enhancement (PE) and mean signal enhancement ratio (SER) in distance bands of 5 mm from the tumor edge. Global PE and SER were calculated by averaging all stromal bands 5 to 40 mm from tumor. Proximity-dependent PE and SER were analyzed using a linear mixed effects model and Cox proportional hazards model for recurrence-free survival. Results The mixed effects model displayed a decreasing radial trend in PE at both V1 and V2. An increasing trend was less pronounced in SER. Survival analysis showed that the hazard ratio estimates for each unit decrease in global SER was statistically significant at V1 [estimated hazard ratio = 0.058, 95% Wald CI (0.003, 1.01), likelihood ratio p = 0.03]; but was not so for V2. Conclusions These findings show that stromal tissue outside the tumor can be quantitatively characterized by DCE-MRI, and suggest that stromal enhancement measurements may be further developed for use as a potential predictor of recurrence/disease-free survival following therapy.

[1]  Norman Boyd,et al.  The Association of Measured Breast Tissue Characteristics with Mammographic Density and Other Risk Factors for Breast Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[2]  N M Hylton,et al.  Vascularity assessment of breast lesions with gadolinium-enhanced MR imaging. , 1999, Magnetic resonance imaging clinics of North America.

[3]  T. Tlsty,et al.  Know thy neighbor: stromal cells can contribute oncogenic signals. , 2001, Current opinion in genetics & development.

[4]  L. Esserman,et al.  MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. , 2005, AJR. American journal of roentgenology.

[5]  Catherine Klifa,et al.  Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy. , 2008, AJR. American journal of roentgenology.

[6]  S J Graham,et al.  Magnetic resonance properties of ex vivo breast tissue at 1.5 T , 1997, Magnetic resonance in medicine.

[7]  Satoshi Matsumoto,et al.  Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas , 2002, Nature Genetics.

[8]  Wendy B DeMartini,et al.  Diffusion tensor MRI: Preliminary anisotropy measures and mapping of breast tumors , 2010, Journal of magnetic resonance imaging : JMRI.

[9]  Robert Gray,et al.  Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer Prognosis , 1992 .

[10]  C. Klifa,et al.  Quantification of breast tissue index from MR data using fuzzy clustering , 2004, The 26th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[11]  Catherine Klifa,et al.  Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI. , 2011, Integrative biology : quantitative biosciences from nano to macro.

[12]  Ying Lu,et al.  Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging. , 2008, Radiology.

[13]  A. Karsan,et al.  Inhibition of tumor cell invasion and angiogenesis by motuporamines. , 2001, Cancer research.

[14]  N. Hylton Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Anthony J. Guidi,et al.  Vascular permeability factor (Vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast , 1997, Cancer.

[16]  N. Boyd,et al.  Mammographic densities and breast cancer risk. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  N M Hylton,et al.  Semi-automated analysis for MRI of breast tumors. , 1999, Studies in health technology and informatics.

[18]  Andreas Makris,et al.  Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy. , 2011, Radiology.

[19]  A. Harris,et al.  The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. , 1997, Cancer research.

[20]  Dwight G Nishimura,et al.  High-resolution diffusion-weighted magnetic resonance imaging in patients with locally advanced breast cancer. , 2012, Academic radiology.

[21]  Ying Lu,et al.  Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. , 2002, AJR. American journal of roentgenology.

[22]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[23]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[24]  Andrew H. Beck,et al.  Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival , 2011, Science Translational Medicine.